KR20150042280A - 낮은 aag를 보유한 환자에서 암 치료 용도의 arry-520 - Google Patents

낮은 aag를 보유한 환자에서 암 치료 용도의 arry-520 Download PDF

Info

Publication number
KR20150042280A
KR20150042280A KR20157006504A KR20157006504A KR20150042280A KR 20150042280 A KR20150042280 A KR 20150042280A KR 20157006504 A KR20157006504 A KR 20157006504A KR 20157006504 A KR20157006504 A KR 20157006504A KR 20150042280 A KR20150042280 A KR 20150042280A
Authority
KR
South Korea
Prior art keywords
patient
aag
arry
cancer
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20157006504A
Other languages
English (en)
Korean (ko)
Inventor
카린 브라운
로날드 비. 프랭클린
개리 피. 힝고라니
케빈 에스. 리트윌러
브라이언 제이. 턴퀴스트
던컨 에이치. 월커
Original Assignee
어레이 바이오파마 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50101460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150042280(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 어레이 바이오파마 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20150042280A publication Critical patent/KR20150042280A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR20157006504A 2012-08-13 2013-08-13 낮은 aag를 보유한 환자에서 암 치료 용도의 arry-520 Withdrawn KR20150042280A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261682682P 2012-08-13 2012-08-13
US61/682,682 2012-08-13
US201261734149P 2012-12-06 2012-12-06
US61/734,149 2012-12-06
US201361829779P 2013-05-31 2013-05-31
US61/829,779 2013-05-31
PCT/US2013/054807 WO2014028543A1 (en) 2012-08-13 2013-08-13 Arry-520 for use in treating cancer in a patient with low aag

Publications (1)

Publication Number Publication Date
KR20150042280A true KR20150042280A (ko) 2015-04-20

Family

ID=50101460

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20157006504A Withdrawn KR20150042280A (ko) 2012-08-13 2013-08-13 낮은 aag를 보유한 환자에서 암 치료 용도의 arry-520

Country Status (19)

Country Link
US (1) US20150231117A1 (https=)
EP (1) EP2882436A1 (https=)
JP (1) JP2015524845A (https=)
KR (1) KR20150042280A (https=)
CN (1) CN104869995A (https=)
AU (1) AU2013302762A1 (https=)
BR (1) BR112015003192A2 (https=)
CA (1) CA2881937A1 (https=)
CL (1) CL2015000348A1 (https=)
CR (1) CR20150134A (https=)
HK (1) HK1206275A1 (https=)
IL (1) IL237227A0 (https=)
IN (1) IN2015KN00676A (https=)
MX (1) MX2015002018A (https=)
NZ (1) NZ631362A (https=)
PH (1) PH12015500306A1 (https=)
RU (1) RU2617392C2 (https=)
SG (1) SG11201501106TA (https=)
WO (1) WO2014028543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
RS50670B (sr) * 2004-05-21 2010-06-30 Novartis Vaccines And Diagnostics Inc. Supstitucionisani derivati hinolina kao mitotički kinezinski inhibitori
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US9561214B2 (en) 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis
CN104958292B (zh) * 2008-10-16 2018-10-16 阵列生物制药公司 用于在治疗中增加凋亡的有丝分裂抑制剂

Also Published As

Publication number Publication date
BR112015003192A2 (pt) 2017-08-08
MX2015002018A (es) 2015-10-09
US20150231117A1 (en) 2015-08-20
JP2015524845A (ja) 2015-08-27
CA2881937A1 (en) 2014-02-20
PH12015500306A1 (en) 2015-04-20
HK1206275A1 (en) 2016-01-08
CN104869995A (zh) 2015-08-26
NZ631362A (en) 2016-09-30
AU2013302762A1 (en) 2014-10-02
CL2015000348A1 (es) 2015-04-24
EP2882436A1 (en) 2015-06-17
CR20150134A (es) 2015-05-06
IN2015KN00676A (https=) 2015-07-17
RU2617392C2 (ru) 2017-04-24
IL237227A0 (en) 2015-04-30
RU2015108740A (ru) 2016-09-27
WO2014028543A1 (en) 2014-02-20
SG11201501106TA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
AU2011205343B2 (en) Methods for predicting response of triple-negative breast cancer to therapy
CN102667478B (zh) 用于检测致癌融合蛋白的邻近介导试验
EP2179291B1 (en) Drug selection for lung cancer therapy using antibody-based arrays
US10517844B2 (en) Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
JP2011503071A (ja) Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる子宮がん及び卵巣がんの治療
JP2011503111A (ja) Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
JP2014503821A (ja) 抗体ベースのアレイを用いる悪性がんの療法のための薬剤選択
KR20140020318A (ko) 위암 환자의 생존률 예측 및 개선 방법
Zhang et al. Discovery of an OTUD3 inhibitor for the treatment of non-small cell lung cancer
HK1249866A1 (zh) 用他塞利昔布进行治疗的方法
Hebert et al. Esomeprazole enhances the effect of ionizing radiation to improve tumor control
JP2018537519A (ja) 癌の治療のための合理的併用療法
Peng et al. Identification of Bruceine A as a novel HSP90AB1 inhibitor for suppressing hepatocellular carcinoma growth
KR20150042280A (ko) 낮은 aag를 보유한 환자에서 암 치료 용도의 arry-520
CN121646480A (zh) 治疗p53基因突变或缺陷阴性癌症、肿瘤患者
US20160025730A1 (en) Methods of selecting combination therapy for colorectal cancer patients
CN121969391A (zh) 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症
US20160305944A1 (en) Polyp recurrence
HK1178602B (en) Methods for predicting response of triple-negative breast cancer to therapy
HK1175529B (en) Proximity-mediated assays for detecting oncogenic fusion proteins
HK1175529A (en) Proximity-mediated assays for detecting oncogenic fusion proteins

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150313

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid